A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.

Get tomorrow's stamps

Free daily email. Come back without waiting on Google.

Evidence test

FinchFile doesn't ask you to trust us. It shows you the evidence. This stamp is Depends. Read the trail, then decide.

• 247wallst ↗Other source

  Dose Check · Oct 1, 4:05 PM

Cite this stamp

Paste the link when you argue the claim. Other sites can embed the badge.

https://finchfile.com/story/c6158073f5

Related stamps

More FinchFile checks in Health.

• DependsSTAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the worldDepends
• DependsNew Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?Depends
• DependsYou’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Si…Depends